Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCC

Cancer shared this article with you from Inoreader Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCC Via MedWorm Cancer & Oncology Clinical Trials Condition:   Hepatocellular Carcinoma Intervention:   Drug: Anti-angiogenic agents plus anti-PD-1/PD-L1 antibodies Sponsor:   Shanghai Zhongshan Hospital Recruiting (Source: ClinicalTrials.gov) View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD.

Cancer shared this article with you from Inoreader CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD. Via MedWorm Cancer & Oncology Clinical Trials Condition:   CLL Interventions:   Drug: ibrutinib, venetoclax, obinutuzumab;   Drug: ibrutinib, venetoclax Sponsors:   Stichting Hemato-Oncologie voor Volwassenen Nederland;   Nordic Lymphoma Group Not yet recruiting (Source: ClinicalTrials.gov) View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Identification of Genetic Determinants for Treatment Resistance/Sensitivity and/or Toxicity in Adjuvant Setting for HER2 Positive Breast Cancer

Cancer shared this article with you from Inoreader Identification of Genetic Determinants for Treatment Resistance/Sensitivity and/or Toxicity in Adjuvant Setting for HER2 Positive Breast Cancer Via MedWorm Cancer & Oncology Clinical Trials Condition:   HER2-positive Breast Cancer Intervention:   Other: Blood sample for genetic analysis Sponsor:   Institut de cancérologie Strasbourg Europe Not yet recruiting (Source: ClinicalTrials.gov) View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)

Cancer shared this article with you from Inoreader Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC) Via MedWorm Cancer & Oncology Clinical Trials Condition:   Lung Cancer, Nonsmall Cell Interventions:   Drug: Pembrolizumab;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Pemetrexed Sponsor:   McGill University Health Centre/Research Institute of the McGill University Health Centre Not yet recruiting (Source: ClinicalTrials.gov) View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Intestinal Microbiota in Prostate Cancer Patients as a Biomarker for Radiation-INduced Toxicity (IMPRINT)

Cancer shared this article with you from Inoreader Intestinal Microbiota in Prostate Cancer Patients as a Biomarker for Radiation-INduced Toxicity (IMPRINT) Via MedWorm Cancer & Oncology Clinical Trials Conditions:   Prostate Cancer;   Prostate Adenocarcinoma;   Prostatic Neoplasms Interventions:   Other: Collection of human biofluids;   Other: Patient reported outcome measures Sponsor:   University Hospital, Ghent Recruiting (Source: ClinicalTrials.gov) MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Anti-CD19 FasT CAR-T Cell Therapy for B Cell NHL

Cancer shared this article with you from Inoreader Anti-CD19 FasT CAR-T Cell Therapy for B Cell NHL Via MedWorm Cancer & Oncology Clinical Trials Condition:   Lymphoma, Non-Hodgkin Intervention:   Biological: anti-CD19 FasT CAR-T cells Sponsors:   Xinqiao Hospital of Chongqing;   Gracell Biotechnologies (Shanghai) Co., Ltd;   920th Hospital of Joint Logistics Support Force;   The Second Affiliated Hospital of Chongqing Medical University;   The Affiliated Hospital Of Guizhou Medical University;   The Second Affiliated Ho spital of Kunming Medical University;   Chongqing University Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov) View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis

Cancer shared this article with you from Inoreader Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis Via MedWorm Cancer & Oncology Clinical Trials Conditions:   Breast Cancer;   HER2-positive Breast Cancer Interventions:   Drug: Pyrotinib Plus And;   Drug: Trastuzumab;   Drug: Abraxane Sponsor:   Shandong Cancer Hospital and Institute Not yet recruiting (Source: ClinicalTrials.gov) MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Impact of (Neo)Adjuvant Therapy Associating Anthracyclines and Taxanes With or Without Trastuzumab on Skeletal Muscle in Breast Cancer Patients

Cancer shared this article with you from Inoreader Impact of (Neo)Adjuvant Therapy Associating Anthracyclines and Taxanes With or Without Trastuzumab on Skeletal Muscle in Breast Cancer Patients Via MedWorm Cancer & Oncology Clinical Trials Condition:   Breast Cancer Interventions:   Other: Microbiopsy sample;   Other: Muscle echography, Maximal strength, Body composition, Quality of life and Physical activity level Sponsors:   Institut de cancérologie Strasbourg Europe;   UR 3072 - Mitochondries, Stress oxydant, Protection musculaire Recruiting (Source: ClinicalTrials.gov) View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

De-Escalation Protocol Of HPV Mediated Oropharyngeal Squamous Cell Carcinoma

Cancer shared this article with you from Inoreader De-Escalation Protocol Of HPV Mediated Oropharyngeal Squamous Cell Carcinoma Via MedWorm Cancer & Oncology Clinical Trials Conditions:   HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Clinical Stage;   Oropharynx Cancer Interventions:   Procedure: Transoral robotic surgery;   Drug: Cisplatin - Dose Level 1;   Drug: Cisplatin - Dose Level 2;   Radiation: Dose Level 1;   Radiation: Dose Level 2 Sponsor:   Nebraska Methodist Health System Recruiting (Source: ClinicalTrials.gov) View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

PREselection of Patients at Risk for COgnitive DEcline After Radiotherapy Using Advanced MRI

Cancer shared this article with you from Inoreader PREselection of Patients at Risk for COgnitive DEcline After Radiotherapy Using Advanced MRI Via MedWorm Cancer & Oncology Clinical Trials Condition:   Meningioma Intervention:   Other: PRECODE-MRI Sponsors:   Maastricht Radiation Oncology;   Maastricht University Medical Center;   ZonMw: The Netherlands Organisation for Health Research and Development Not yet recruiting (Source: ClinicalTrials.gov) View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

OH2 Oncolytic Viral Therapy in Pancreatic Cancer

Cancer shared this article with you from Inoreader OH2 Oncolytic Viral Therapy in Pancreatic Cancer Via MedWorm Cancer & Oncology Clinical Trials Condition:   Pancreatic Cancer Intervention:   Biological: OH2 injection Sponsor:   Wuhan Binhui Biotechnology Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov) View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Silicon Microsieve Device vs Cell Surface Marker-based Platform for the Isolation of Pancreatic Cancer CTCs

Cancer shared this article with you from Inoreader Silicon Microsieve Device vs Cell Surface Marker-based Platform for the Isolation of Pancreatic Cancer CTCs Via MedWorm Cancer & Oncology Clinical Trials Condition:   Pancreatic Cancer Interventions:   Device: Microsieve device;   Device: Cell surface marker-based platform Sponsors:   Singapore General Hospital;   Agency for Science, Technology and Research Not yet recruiting (Source: ClinicalTrials.gov) View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

A Study to Evaluate Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With HCC at High Risk of Recurrence After Surgical Resection or Ablation

Cancer shared this article with you from Inoreader A Study to Evaluate Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With HCC at High Risk of Recurrence After Surgical Resection or Ablation Via MedWorm Cancer & Oncology Clinical Trials Condition:   Hepatocellular Carcinoma (HCC) Interventions:   Drug: Camrelizumab;   Drug: Apatinib Sponsor:   Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov) View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.